Key result
Warfarin and novel oral anticoagulants, including dabigatran, rivaroxaban, apixaban, and edoxaban, represent the current standard and new developments in oral anticoagulation therapy.
A commentary reviewing the current status and standards for oral anticoagulants, including warfarin and NOACs.
Answers are grounded in this paper and cite their sources.
Reaffirms warfarin and NOACs as anticoagulation standards; leaves open optimal agent selection across patient subgroups.
This commentary focuses on the status of oral anticoagulants, namely, warfarin and the novel oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban.
No takes yet. Share an insight, caveat, or question.
LJ Lesko (2016) studied this question. Warfarin and novel oral anticoagulants, including dabigatran, rivaroxaban, apixaban, and edoxaban, represent the current standard and new developments in oral anticoagulation therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: